gila monster venom glp-1 Weight Loss and monsters. Who knew? On a Mission to Heal

This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide

Research shows a 40-fold increase in these drugs from 2017 to 2021, estimating that roughly 2-3% of the United States is now on either Ozempic or Mounjaro

News from food industry suppliers

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP

Researchers conducted a prospective single-center cohort study of adults with a BMI of 27 kg/m2 or higher using liraglutide (Victoza/Saxenda, Novo Nordisk) or semaglutide (Ozempic/Wegovy, Novo Nordisk)